- Home
- GIGM vs BIVI Comparison
GIGM vs BIVI Comparison
Compare GIGM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | BIVI |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 13.3M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GIGM | BIVI |
|---|---|---|
| Price | $1.43 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.5K | ★ 218.2K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $1.06 |
| 52 Week High | $1.89 | $9.09 |
Technical Indicators
Market Signals| Indicator | GIGM | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 41.55 |
| Support Level | $1.32 | $1.22 |
| Resistance Level | $1.50 | $1.73 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 25.00 | 12.65 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.